厄贝沙坦治疗高血压早期肾损害的疗效观察
Analysis of clinical efficacy of irbesartan in the treatment of early renal damage of hypertension
-
摘要: 目的：探讨厄贝沙坦治疗高血压早期肾损害的临床疗效。方法：选取80例高血压早期肾损害病人，按照随机数字表法分为2组：氨氯地平组40例，给予氨氯地平治疗；厄贝沙坦组40例，给予厄贝沙坦治疗。治疗12周后比较2组的血压、肾功能、血管内皮功能。结果：2组病人收缩压、舒张压和平均动脉压均明显低于治疗前（P<0.01），组间比较差异均无统计学意义（P>0.05）；厄贝沙坦组24h尿蛋白排泄率及β2微球蛋白水平均明显低于氨氯地平组，一氧化氮、内皮舒张功能均明显高于氨氯地平组，内皮素水平低于氨氯地平组（P<0.05~P<0.01）；2组病人不良反应发生率差异无统计学意义（P>0.05）。结论：厄贝沙坦与氨氯地平均可有效降低高血压早期肾损害的血压，但在改善肾功能、血管内皮功能方面，厄贝沙坦的效果更好，值得临床重视。Abstract: Objective:To investigate the clinical efficacy of irbesartan in the treatment of early renal damage of hypertension.Methods:Eighty hypertensive patients with early renal damage were randomly divided into the amlodipine group and irbesartan group(40 cases each group).The amlodipine group and irbesartan group were treated with amlodipine and irbesartan,respectively.After 12 weeks of treatment,the blood pressure,renal function and vascular endothelial function were compared between two groups.Results:The systolic blood pressure,diastolic blood pressure and mean arterial pressure in two groups after treatment were significantly lower than before treatment(P<0.01),there was no statistical significance between two groups(P>0.05).The levels of 24 h UAER and β2-MG in irbesartan group were significantly lower than those in amlodipine group,the NO and vascular endothelial function in irbesartan group were significantly higher than those in amlodipine group,and the ET level in irbesartan group was significantly lower than that in amlodipine group(P<0.05 to P<0.01).The difference of the incidence rate of adverse reaction between two groups was not statistically significant(P>0.05).Conclusions:Irbesartan and amlodipine can effectively reduce the blood pressure in hypertension patients with early renal damage.The effect of irbesartan in improving renal and vascular endothelial function is better than that of amlodipine,and the use of irbesartan is worthy of attention.
-
Key words:
- hypertension /
- kidney damage /
- irbesartan /
- vascular endothelial function
-
[1] 刘永春.老年高血压肾损害危险因素的相关性研究[J].实用心脑肺血管病杂志,2013,21(10):20. [2] 梁少姗,乐伟波,梁丹丹,等.高血压肾损害的临床病理特点及预后[J].肾脏病与透析肾移植杂志,2015,24(1):32. [3] 孙丽双,肖青,赵庆高,等.高血压早期肾损害相关检测指标[J].中国心血管病研究,2015,13(5):398. [4] 袁伟杰,崔若兰.对高血压肾损害临床应进一步思考的问题[J].中华肾脏病杂志,2005,21(10):572. [5] 李伟,陆峰,彭伟,等.自发性高血压大鼠早期肾损害与血管内皮功能标志物的相关性研究[J].辽宁中医杂志,2011,38(6):1224. [6] 朱华军.卡托普利治疗老年高血压伴轻度肾损害的疗效及对肾功能转归的影响[J].检验医学与临床,2016,13(8):1055. [7] 中国高血压基层管理指南修订委员会.中国高血压基层管理指南(2014年修订版)[J].中华高血压杂志,2015,23(1):24. [8] 王建彬,戴小华,杨帆,等.养肝益水颗粒对高血压早期肾损害尿微量蛋白的影响[J].安徽中医药大学学报,2008,6(5):23. [9] 谢玉霞,武刚.吲达帕胺联合氨氯地平治疗高血压合并冠心病病人的疗效观察[J].重庆医学,2013,42(6):640. [10] 李莉.厄贝沙坦氢氯噻嗪片治疗原发性高血压的临床观察[J].中西医结合心脑血管病杂志,2009,7(2):234. [11] 程水进,吴继雄,陈万林.坎地沙坦和氨氯地平对原发性高血压早期肾损害的影响[J].安徽医药,2011,15(4):495. [12] 陈绿娥.厄贝沙坦治疗原发性高血压肾功能损害疗效观察[J].现代中西医结合杂志,2010,19(21):2644. [13] 瞿玲玲,张贵生,叶军.厄贝沙坦治疗原发性高血压肾损害疗效观察[J].现代中西医结合杂志,2011,20(31):3941. [14] 吕留强,赵立,李晓波,等.厄贝沙坦/氢氯噻嗪对原发性高血压伴早期肾损害尿微量白蛋白和N-乙酰-β-D-氨基葡萄糖苷酶的影响[J].实用心脑肺血管病杂志,2012,20(1):34. [15] 黄文胜,杜礼兵,冷利华.厄贝沙坦对高血压病人尿微量蛋白排泄的影响[J].安徽医学,2009,30(12):1460. [16] 戴凯琦,周其成,王庆平.安博维治疗原发性轻中度高血压临床观察[J].中国实用内科杂志,2010,30(s1):70. [17] 陶军.高血压与血管内皮功能[J].中国实用内科杂志,2009,5(9):3024. [18] 余秀兰,赵华云,陈伟强,等.高血压病人尿微量蛋白水平与血管内皮功能的关系[J].现代检验医学杂志,2010,25(1):156. [19] 陈岚,任骞,徐进,等.苯磺酸左旋氨氯地平对原发性高血压病人血管内皮功能的影响[J].陕西医学杂志,2016,45(2):241. [20] 王建美.观察ARB对高血压病人血管内皮功能的影响[D].太原:山西医科大学,2015. [21] 李慧颖,李静.厄贝沙坦用于原发性高血压早期肾损害治疗效果观察[J].山东医药,2014,54(30):54. -
点击查看大图
计量
- 文章访问数: 4219
- HTML全文浏览量: 596
- PDF下载量: 16
- 被引次数: 0
下载:
